Nina Mitchell, MA MB BChir MSc

Executive Medical Director
Biomarin
London, United Kingdom

Disclosure information not submitted.

Presentation(s):

• SUN-212 - BMN 333 Achieves High Sustained Released Vosoritide Exposure with Favorable Safety: Phase 1 Results That Support Phase 2/3 Trials in Achondroplasia

  Sunday, June 14, 2026
  9:00 AM - 4:00 PM CT